Comments
Johnson & Johnson drug slows prostate cancer spread by 58 percent: trial
02.06.2012. | CHICAGO (Reuters) - A trial of Johnson & Johnson's prostate cancer pill, Zytiga, found that it slowed the spread of the disease by 58 percent in men who had stopped responding to hormonal drugs but not yet treated with chemotherapy, potentially offering new hope for patients who see their cancer return.
......
